RECRUITINGOBSERVATIONAL

An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease

A Post-marketing Observational Study for ABBV-951 in Patients Diagnosed With Advanced Parkinson's Disease (aPD)

About This Trial

Parkinson's disease (PD) is a neurological condition, which affects the brain. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to assess how safe and effective ABBV-951 is in treating participants with Parkinson's disease in real world setting. ABBV-951 is an approved drug being developed for the treatment of PD in Japan. Approximately 250 adult participants over 15 years with a diagnosis of PD who are prescribed ABBV-951 by their physicians will be enrolled in this study across Japan. Participants will receive ABBV-951 as prescribed their physician and followed for 52 weeks. There is expected to be no additional burden for participants in this trial. Study visits may be conducted on-site or virtually as per standard of care.

Who May Be Eligible (Plain English)

Who May Qualify: - Diagnosed with advanced Parkinson's disease (aPD). - Prescribed ABBV-951 as physicians' decision according to the approved label for treatment of aPD. - Given willing to sign a consent form (or by her/his legal representative, if it's a requirement from the participating hospital/clinic) for participating this study. Who Should NOT Join This Trial: - Prior treatment with ABBV-951 for PD. - Currently participating in interventional clinical trials. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Diagnosed with advanced Parkinson's disease (aPD). * Prescribed ABBV-951 as physicians' decision according to the approved label for treatment of aPD. * Given informed consent (or by her/his legal representative, if it's a requirement from the participating hospital/clinic) for participating this study. Exclusion Criteria: * Prior treatment with ABBV-951 for PD. * Currently participating in interventional clinical trials.

Locations (16)

Saiseikai Matsuyama Hospital /ID# 276259

Matsuyama, Ehime, Japan

National Hospital Organization Asahikawa Medical Center /ID# 269115

Asahikawa, Hokkaido, Japan

Ryugasaki Saiseikai Hospital /ID# 264435

Ryūgasaki, Ibaraki, Japan

University of Tsukuba Hospital /ID# 268353

Tsukuba, Ibaraki, Japan

Okatsu Hospital /ID# 262781

Kagoshima, Kagoshima-ken, Japan

University Hospital Kyoto Prefectural University of Medicine /ID# 267445

Kyoto, Kyoto, Japan

Sendai Nishitaga National Hospital /ID# 268349

Sendai, Miyagi, Japan

Fujimoto General Hospital /ID# 277287

Miyakonojo-shi, Miyazaki, Japan

Shiga University of Medical Science Hospital /ID# 265637

Ōtsu, Shiga, Japan

Dokkyo Medical University Hospital /ID# 269116

Mibu, Tochigi, Japan

Juntendo University Hospital /ID# 264438

Bunkyo-ku, Tokyo, Japan

Nitobe Memorial Nakano General Hospital /ID# 275668

Nakano-ku, Tokyo, Japan

National Center of Neurology and Psychiatry - Kodaira /ID# 267372

Xiaoping City, Tokyo, Japan

National Hospital Organization Utano Hospital /ID# 268350

Kyoto, Japan

Okayama Neurology Clinic /ID# 269117

Okayama, Japan

Municipal Toyonaka Hospital /ID# 271277

Toyonaka, Japan